Keyword: Menarini

Gilead Sign

8. Ranexa

Ranexa has to compete with three other classes of drug that can treat angina, all of which have cheaper generics. Therefore, Evaluate Pharma predicts that the med's worldwide sales, including that from Menarini, will drop dramatically in the coming years to just about $175 million by 2022.
Allergan California

6. Bystolic

Of the $640.5 million Bystolic generated in 2016 for Allergan, $638.8 million came from the U.S. Evaluate Pharma predicts the med will rack up just $214 million in 2022, or $591 million if other versions marketed by Menarini are counted.